SCHEMBL2204973

SCHEMBL2204973

CCOC(=O)c1c(-c2ccccc2-c2ccccc2)c2ccccc2n1CCCOc1cccc2ccccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MARK3 P27448 3/20 0.69
GSK3B P49841 3/20 0.69
CAMK2B Q13554 3/20 0.69
MARK2 Q7KZI7 3/20 0.69
MINK1 Q8N4C8 3/20 0.69
SRPK1 Q96SB4 3/20 0.69
HIPK2 Q9H2X6 3/20 0.69
CDC7 O00311 2/20 0.69
IRAK1 P51617 2/20 0.69
NEK4 P51957 2/20 0.69
MAP4K2 Q12851 2/20 0.69
CDC42BPA Q5VT25 2/20 0.69
TAOK1 Q7L7X3 2/20 0.69
HIPK4 Q8NE63 2/20 0.69
MAP3K20 Q9NYL2 2/20 0.69
EEF2K O00418 1/20 0.69
DAPK3 O43293 1/20 0.69
MAP4K4 O95819 1/20 0.69
PAK4 O96013 1/20 0.69
RPS6KB1 P23443 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2202925 0.92 MARK3 (0.71) MARK3GSK3BCAMK2BMARK2MINK1
SCHEMBL2204047 0.92 MARK3 (0.65) MARK3GSK3BCAMK2BMARK2MINK1
SCHEMBL2204572 0.91 MARK3 (0.80) MARK3GSK3BCAMK2BMARK2MINK1
SCHEMBL2206392 0.89 MARK3 (0.72) MARK3GSK3BCAMK2BMARK2MINK1
SCHEMBL2204504 0.88 MARK3 (0.80) MARK3GSK3BCAMK2BMARK2MINK1
SCHEMBL2204365 0.88 MARK3 (0.76) MARK3GSK3BCAMK2BMARK2MINK1
SCHEMBL2204802 0.87 MARK3 (0.58) MARK3GSK3BCAMK2BMARK2MINK1
SCHEMBL2202644 0.86 MARK3 (0.63) MARK3GSK3BCAMK2BMARK2MINK1
SCHEMBL2202566 0.86 MARK3 (0.59) MARK3GSK3BCAMK2BMARK2MINK1
SCHEMBL2206074 0.86 MARK3 (0.72) MARK3GSK3BCAMK2BMARK2MINK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2134685-B1 7-NONSUBSTITUTED INDOLE DERIVATIVES AS MCL-1 INHIBITORS ABBVIE INC (US) 2015-09-02 EP disclosed
US-8853209-B2 1-oxyalkyl-2-carboxy-7-nonsubstituted indole derivatives ABBVIE INC. (US) 2014-10-07 US disclosed
US-20110263599-A1 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES 2011-10-27 US disclosed
US-7981888-B2 1-oxyalkyl-2-carboxyl-7-nonsubstituted indole derivatives ABBOTT LABORATORIES (US) 2011-07-19 US disclosed
US-20090124616-A1 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES (US) 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124616-A1 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 MARK3 2407/4885GSK3B 938/4885CAMK2B 941/4885
US-20110263599-A1 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 MARK3 2407/4885GSK3B 938/4885CAMK2B 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.